ＡＰ Daratumumab (Genetical Recombination) Vorhyaluronidase Alfa (Genetical Recombination) (15mL／vial) 80vials
ＡＱ Daratumumab (Genetical Recombination) (400mg 20ml／vial) 160vials
ＡＲ Romiplostim (Genetical Recombination) (250μg／vial) 725vials
ＡＳ Burosumab (Genetical Recombination) (30mg 1ml／vial) 45vials
ＡＴ Mogamulizumab (Genetical Recombination) (20mg 5mL／vial) 220vials
ＡＵ Pegfilgrastim (Genetical Recombination) (3.6mg 0.36ml／syringe) 400-syringes
ＡＶ Pegfilgrastim (Genetical Recombination) (3.6mg 0.36mL／kit) 265kits
ＡＷ Aflibercept (Genetical Recombination) (2mg 0.05ml／syringe) 405syringes
ＡＸ Agalsidase Beta BS I.V. Infusion 35mg [JCR] (35mg／vial) 165vials
ＡＹ Agalsidase Beta (Genetical Recombination) (5mg／vial) 275vials
ＡＺ Nivolumab (Genetical Recombination) (240mg 24ml／vial) 910vials
ＢＡ Nivolumab (Genetical Recombination) (240mg 24mL／vial) 170vials
ＢＢ Paclitaxel (100mg／vial) 1,160vials
ＢＣ Trastuzumab Deruxtecan (Genetical Recombination) (100mg／vial) 465vials
ＢＤ Denosumab (Genetical Recombination) (120mg 1mL 1／syringe) 1,175-syringes
ＢＥ Denosumab (Genetical Recombination) (120mg 1.7ml／vial) 1,175vials
ＢＦ Atezolizumab (Genetical Recombination) (1,200mg 20ml／vial) 390vials
ＢＧ Bevacizumab (Genetical Recombination) (400mg 16ml／vial) 480vials
ＢＨ PHESGO Combination for Subcutaneous Injection (10mL／vial) 140vials
ＢＩ Tocilizumab (Genetical Recombination) (200mg 10ml／vial) 1,440vials
ＢＪ Tocilizumab (Genetical Recombination) (162mg 0.9ml／kit) 950cases
ＢＫ Trastuzumab Emtansine (Genetical Recombination) 120vials
ＢＬ Crovalimab (Genetical Recombination) (100mg／vial) 15vials
ＢＭ Trastuzumab emtansine (Genetical Recombination) (160mg／vial) 60vials
ＢＮ Pertuzumab (Genetical Recombination) (420mg 14ml／vial) 95vials
ＢＯ Lanreotide Acetate (120mg／syringe) 185syringes
ＢＰ Ustekinumab (Genetical Recombination) (45mg 0.5ml ／ syringe) 650-syringes
ＢＱ Infliximab (Genetical Recombination) (100mg／vial) 1,715vials
ＢＲ Inebilizumab (Genetical Recombination) (100mg 10mL／vial, 3vials／box) 3boxes
ＢＳ Ganciclovir (500mg／vial) 1,945vials
ＢＴ Ramucirumab (Genetical Recombination) (500mg 50ml／vial) 100vials
ＢＵ Selpercatinib (80mg／CA, 56CA／box) 80boxes
ＢＶ Infliximab BS for I.V. Infusion 100mg "NK" (100mg／vial) 2,380vials
ＢＷ Polyethylene glycol treated human normal immunoglobulin (10g 100ml ／ vial) 640vials
ＢＸ Daunorubicin Hydrochloride Cytarabine (144mg／vial) 55vials
ＢＹ Daunorubicin Hydrochloride (5g 100mL／vial) 810vials
ＢＺ Cytarabine (100mg 5mL／vial) 520-vials
ＣＡ Brentuximab Vedotin (Genetical Recombination) (50mg／vial) 70vials

(4) Delivery period : From 1 April, 2026 through 31 March, 2027

(5) Delivery place : Niigata University Medical and Dental Hospital

(6) Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :

A not come under Article 4 over the past one year and Article 3 of the Regulation concerning the Contract for Niigata University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,

B have the Grade A or Grade B qualification during fiscal 2025 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,

C prove to have obtained license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,

D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the President, National University Corporation Niigata University,

E meet the qualification requirements which President, National University Corporation Niigata University may specify in accordance with Article 5 of the Regulation,

F not be currently under a suspension of business order as instructed by President, National University Corporation Niigata University.

(7) Time limit of tender : 17 : 15　11 March, 2026

(8) Contact point for the notice : Yuji Kaido, Procurement Section, Niigata University Medical and Dental Hospital, 754 Asahimachidori 1-bancho Chuo-ku Niigata-shi 951―8520 Japan, TEL 025―227―2430

(9) Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

入札公告

次のとおり一般競争入札に付します。
令和８年１月13日
分任契約責任者
国立大学法人富山大学
財務施設部長　吉居　真吾

◎調達機関番号　415　◎所在地番号　16

○第 27 号

１　調達内容
(1)　品目分類番号　75
(2)　購入等件名及び数量　富山大学杉谷キャンパス建物清掃業務請負　一式
(3)　調達件名の特質等　入札説明書による。
(4)　履行期間　令和８年７月１日から令和11年６月30日
(5)　履行場所　分任契約責任者が指定する場所
(6)　入札方法　落札決定に当たっては、入札書に記載された金額に当該金額の10パーセントに相当する額を加算した金額（当該金額に１円未満の端数があるときは、その端数金額を切り捨てるものとする。）をもって落札価格とするので、入札者は、消費税及び地方消費税に係る課税事業者であるか免税事業者であるかを問わず、見積もった契約金額の110分の100に相当する金額を入札書に記載すること。

２　競争参加資格
(1)　国立大学法人富山大学契約規則第５条及び第６条の規定に該当しない者であること。なお、未成年者、被保佐人又は被補助人であって、契約締結のために必要な同意を得ている者は、同条中、特別の理由がある場合に該当する。
(2)　国の競争参加資格（全省庁統一資格）において令和７年度に東海・北陸地域の「役務の提供等」のＡ、Ｂ又はＣ等級に格付けされている者であること。なお、当該競争参加資格については、令和７年３月31日付け号外政府調達第57号の官報の競争参加者の資格に関する公示の別表に掲げる申請受付窓口において随時受け付けている。
(3)　調達特定役務に係る迅速なアフターサービスの体制が整備されていることを証明した者であること。
(4)　国立大学法人富山大学契約規則第８条の規定に基づき、契約責任者が定める資格を有する者であること。
(5)　契約責任者から取引停止の措置を受けている期間中の者でないこと。